Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-04-11
2009-06-23
Stockton, Laura L. (Department: 1626)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C548S306100
Reexamination Certificate
active
07550603
ABSTRACT:
Compounds of Formula (I)inhibit the PARP enzyme and are useful for treating a disease or a disorder associated with PARP. Also disclosed are pharmaceutical compositions comprising compounds of Formula (I), methods of treatment comprising compounds of Formula (I), and methods of inhibiting the PARP enzyme comprising compounds of Formula (I).
REFERENCES:
patent: 3864385 (1975-02-01), Feit et al.
patent: 4093726 (1978-06-01), Winn et al.
patent: 6372736 (2002-04-01), Kemp et al.
patent: 6448271 (2002-09-01), Lubisch et al.
patent: 6509365 (2003-01-01), Lubisch et al.
patent: 6696437 (2004-02-01), Lubisch et al.
patent: 6737421 (2004-05-01), Lubish et al.
patent: 7166292 (2007-01-01), Isele et al.
patent: RE39608 (2007-05-01), Lubisch et al.
patent: 2003/0100582 (2003-05-01), Sircar et al.
patent: 3522230 (1985-06-01), None
patent: 3522230 (1987-01-01), None
patent: 38 30 060 (1990-03-01), None
patent: 3830060 (1990-03-01), None
patent: 19916460 (2000-06-01), None
patent: 199 16 460 (2000-10-01), None
patent: 100 21 468 (2001-08-01), None
patent: 10021468 (2001-11-01), None
patent: 1354554 (1971-08-01), None
patent: WO 97/04771 (1997-02-01), None
patent: WO 9839343 (1998-09-01), None
patent: 0026192 (2000-05-01), None
patent: 00/32579 (2000-08-01), None
patent: 00/26192 (2000-11-01), None
patent: 0121615 (2001-03-01), None
patent: WO 01/21615 (2001-03-01), None
patent: WO-01/21615 (2001-03-01), None
patent: WO 01/21634 (2001-03-01), None
patent: WO 01/82877 (2001-11-01), None
patent: WO 02/068407 (2002-09-01), None
patent: WO-02/068407 (2002-09-01), None
patent: 03/002698 (2003-01-01), None
patent: 03020698 (2003-03-01), None
patent: WO 03/094861 (2003-11-01), None
patent: WO 03/106430 (2003-12-01), None
patent: WO 2004/054515 (2004-07-01), None
patent: WO 2004/065370 (2004-08-01), None
patent: 2004098494 (2004-11-01), None
patent: WO 2004/096793 (2004-11-01), None
patent: WO 2004/098494 (2004-11-01), None
Alexy, et al., “Inhibition of ADP-Evoked Platelet Aggregation by Selected Poly(ADP-Ribose) Polymerase Inhibitors”, Journal Cardiovasc Pharmacol 43,(3), 423-431 (2004).
Gilchrist, et al., “Cyclisation of ortho-Substituted N-Arylben zimidoyl Nitrenes. Part 2. Preferential Cyclisations at an ortho-Position Bearing a Methoxycarbonyl Group”, 1979.
Griffin, et al., “Resistance modifying agents. 3. Novel benzimidazole and quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose)polymerase”, Pharmaceutical Sciences, 2(1), 43-47 (1996).
Ohkura, et al., “Mechanism of the Color Reaction betweenm-Dinitrobenzene and Alkali Cyanide. II. Color Reaction Products of 2,4-Dinitroaniline with Postassium Cyanide (Organic Analysis. LXXII1)”, Chem Pharm Bull, 18(11), 2164-2168 (1970).
White, et al., Potentiation of cytotoxic drug activity in human tumor cell lines, by amine-substituted 2-arylbenzimidazol-4-carboxamide PARP-1 inh, 2004.
Burkart, V., et al., “Mice lacking the poly (ADP-ribose) polymerase gene are resistant to pancreatic beta-cell destruction and diabetes development induced by streptozocin”,Nat. Med., 5(3):314-319 (1999).
Chen, G. & Pan, Q.-c., “Potentiation of the antitumor activity of cisplatin in mice by 3-aminobenzamide and nicotinamide”,Cancer Chem. Pharm., 22:303-307 (1988).
Ehrlich, W., et al., “Inhibition of the induction of collagenase by interleukin-1β in cultured rabbit synovial fibroblasts after treatment with the poly(ADP-ribose)-polymerase inhibitor 3-aminobenzamide”,Rheumatol Int., 15:171-172 (1995).
Cuzzocrea, S., et al., “Protective effects of 3-aminobenzamide, an inhibitor of poly (ADP-ribose) synthase in a carrageenan-induced model of local inflammation”,Eur. J. of Pharm., 342:67-76 (1998).
IUPAC Comm. On Nomenclature of Organic Chemistry, “Rules for the Nomenclature of Organic Chemistry”,Section E: Stereochemistry, 13-30 (1974).
Kröger, H., et al., “Synergistic Effects of Thalidomide and Poly(ADP-Ribose) Polymerase Inhibition of Type II Collagen-Induced Arthritis in Mice”,Inflammation, 20(2):203-215 (1996).
Poste, G., et al., “Lipid Vesicles as Carriers for Introducing Biologically Active Materials into Cells”,Methods in Cell Biology, XIV:33-71 (1976).
Szabo, C., et al., “Protection against peroxynitrite-induced fibroblast injury and arthritis development by inhibition of poly(ADP-ribose) synthase”,Proc. Natl. Acad. Sci. USA, 95:3867-3872 (1998).
Thiemermann, C., et al., “Inhibition of the activity of poly (ADP ribose) synthhetase reduces ischemia-reperfusion injury in the heart and skeletal muscle”,Proc. Natl. Acad. Sci. USA, 94:679-683 (1997).
Weltin, D., et al., “Immunosuppressive Activities of 6(5H)-Phenanthridinone, A New Poly(ADP-Ribose)Polymerase Inhibitor”,Int. J. Immunopharmac., 17(4):265-271 (1995).
Co-Pending U.S. Appl. No. 09/830,992, filed May 3, 2001.
Co-Pending U.S. Appl. No. 10/935,683, filed Sep. 7, 2004.
Co-Pending U.S. Appl. No. 11/401,635, filed Apr. 11, 2006.
Co-Pending U.S. Appl. No. 11/536,994, filed Sep. 29, 2006.
Co-Pending U.S. Appl. No. 11/560,166, filed Nov. 15, 2006.
Co-Pending U.S. Appl. No. 11/743,200, filed May 2, 2007.
Search Report No. 20030374, Jun. 13, 2003.
Search Report No. 20030487, Sep. 19, 2003.
Search Report No. 20050150, Apr. 22, 2005.
Search Report No. 20050207, May 27, 2005.
Gandhi Virajkumar B.
Giranda Vincent L.
Gong Jianchun
Penning Thomas D.
Zhu Gui-Dong
Abbott Laboratories Inc.
Steele Gregory W.
Stockton Laura L.
LandOfFree
1H-benzimidazole-4-carboxamides substituted with a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 1H-benzimidazole-4-carboxamides substituted with a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1H-benzimidazole-4-carboxamides substituted with a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4079002